What the FDA won't tell you about your medications (transcript, Propublica)
The FDA has long claimed that generic drugs are as safe and effective as brand-name medications, but ProPublica's investigation reveals that this may not always be true. Internal FDA inspection reports uncovered unsanitary conditions and fraudulent testing at overseas drug manufacturing plants. Despite knowing about these issues, the FDA allowed some facilities to continue exporting medications to the U.S. without informing the public.
- ▪The FDA has publicly maintained that generic drugs are as safe and effective as brand-name versions.
- ▪ProPublica obtained FDA inspection reports showing serious quality issues at overseas drug manufacturing facilities, including unsanitary conditions and falsified test results.
- ▪The FDA chose not to disclose these findings and allowed some problematic factories to keep supplying drugs to the U.S. market.
- ▪Inspectors reported issues such as pigeons defecating on sterilized equipment and laboratories cheating on quality control tests.
- ▪ProPublica’s investigation raises concerns about transparency and the reliability of generic medications in the U.S. supply chain.
Opening excerpt (first ~120 words) tap to expand
Paper Trail What the FDA Won’t Tell You About Your Medications For years, the Food and Drug Administration told the public that generic medications are just as safe and effective as the brand-name versions. But ProPublica reporters uncovered information that proves this isn’t always true. hosted by Jessica Lussenhop, with reporting by Debbie Cenziper and Megan Rose May 14, 2026, 8:30 am Follow on Apple Podcasts Follow on Spotify {"componentName":"ShareToolsRebrand","props":{"pageTitle":"","pageUrl":"https://www.propublica.org/podcast/what-fda-wont-tell-you-generic-drugs-safety"},"contextArray":[]} {"componentName":"DarkModeToggleRebrand","props":{},"contextArray":[]} Contrast Change Appearance AutoLightDark Description For years, the Food and Drug Administration told the public that…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ProPublica.
Discussion
0 commentsMore from ProPublica
